Annual Report

Overview

The report covers FY2023-24, highlighting consolidated total revenue of INR 2,881 crore and continued investment in novel antibiotics and biotechnology. It reports 24 patents filed and 30 granted during the year, while WCK 5222/ZAYNICH compassionate-use treatment achieved 100% clinical and microbiological success in 30 patients. The report also includes a BRSR for standalone India operations, reporting 10,052.28 tCO2e Scope 1 and 55,818.85 tCO2e Scope 2 emissions; no assurance was obtained.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Publication date: 28 May 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services